XNYS
CNMD
Market cap1.32bUSD
Oct 09, Last price
44.42USD
1D
1.99%
1Q
17.23%
Jan 2017
2.13%
Name
Conmed Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Related entities
Subsidiaries (3)
CONMED EUROPE
LINVATEC CANADA ULC
CONMED LINVATEC AUSTRALIA PTY LTD
Key people
Independent Chairman of the Board · since 2025
Hollie Foust
Executive Vice President, General Counsel and Corporate Secretary · since 2024
Brent Lalomia
Executive Vice President, Regulatory Affairs, Quality Assurance, Clinical Affairs, and Commercial Operations · since 2025
Peter Shagory
Executive Vice President - Strategy and Corporate Development · since 2015
Richard Glaze
Chief Information Officer · since 2023
Edward Clifford
Vice President - Global Manufacturing · since 2023
Stephan Epinette
Vice President and General Manager, International · since 2020
Andrew Moller
Vice President, Corporate Controller · since 2025
Johonna Pelletier
Treasurer and Vice President - Tax · since 2015
John Ferrell
Executive Vice President, Human Resources · since 2022
Patrick Beyer
President, Chief Executive Officer, Director · since 2025
David Bronson
Independent Director · since 2015
Brian Concannon
Independent Director · since 2013
Charles Farkas
Independent Director · since 2014
Independent Director · since 2025
Independent Director · since 2025
Barbara Schwarzentraub
Independent Director · since 2019
Legal address
CORPORATION TRUST CENTER 1209 ORANGE ST
Wilmington, DE 19801
US
Wilmington, DE 19801
US
Headquarters
200 West Street
New York, NY 10282
US
New York, NY 10282
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||